Tirzepatide, the first single-molecule, dual GIP and GLP-1 receptor agonist, is licensed in the UK for the treatment of both type 2 diabetes and obesity, and has been demonstrated to slow gastric emptying, increase insulin sensitivity and glucose-dependent insulin secretion, and decrease glucagon secretion and appetite
The FDA has issued warning letters to manufacturers selling glutathione injections contaminated with bacterial endotoxins or mislabeled potency
& Koehle, M
m6A modification inhibits miRNAs intracellular function, favoring their extracellular export for intercellular communication
doi:10.1517/17425255.2013.786042 Kom AM, Chandran MM, Tungate Lopez SS, Buse JB, Klein KR
Begin or continue resistance training at least three times per week